Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBIG for Sustained Clinical Cure in Chronic Hepatitis B
NCT07328711Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hepatitis B immune globulin in Chronic Hepatitis B (CHB) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Sustained HBsAg seroclearance rate at 48 weeks. Started Jan 2026; status: recruiting.
02
Drugs
hepatitis B immune globulin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07328711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328711.